New Podcast Episode: The Importance of IPF Clinical Trials, feat. Patient Advocate Murray Walz
source: shutterstock.com

New Podcast Episode: The Importance of IPF Clinical Trials, feat. Patient Advocate Murray Walz

Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back with a new episode. This week, Colby is sitting down with Murray Walz, a…

Continue Reading New Podcast Episode: The Importance of IPF Clinical Trials, feat. Patient Advocate Murray Walz
Living with Pulmonary Fibrosis: Adam’s Rare Patient Story (and World Record Attempt!)
source: shutterstock.com

Living with Pulmonary Fibrosis: Adam’s Rare Patient Story (and World Record Attempt!)

Written by Adam Faatz Imagine not being able to breathe and spending nine days climbing the world's tallest freestanding mountain. That is my story, and that is my goal. Sixty-five…

Continue Reading Living with Pulmonary Fibrosis: Adam’s Rare Patient Story (and World Record Attempt!)
Living with Pulmonary Fibrosis: Adam’s Rare Patient Story (and World Record Attempt!)
source: shutterstock.com

Living with Pulmonary Fibrosis: Adam’s Rare Patient Story (and World Record Attempt!)

Written by Adam Faatz Imagine not being able to breathe and spending nine days climbing the world's tallest freestanding mountain. That is my story, and that is my goal. Sixty-five…

Continue Reading Living with Pulmonary Fibrosis: Adam’s Rare Patient Story (and World Record Attempt!)
Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF
kalhh / Pixabay

Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF

  The U.S. FDA has approved two treatments for people living with idiopathic pulmonary fibrosis (IPF). These therapies—Esbriet (pirfenidone) and Ofev (nintedanib)—both work to reduce fibrosis, or scarring, in the…

Continue Reading Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF
Study Found Ziritaxestat Ineffective in Improving IPF Lung Function
source: pixabay.com

Study Found Ziritaxestat Ineffective in Improving IPF Lung Function

Both Ofev (nintedanib) and Esbriet (pirfenidone) are FDA-approved to treat individuals living with mild, moderate, or severe idiopathic pulmonary fibrosis (IPF). The treatments work by preventing fibrosis (scarring) and stopping…

Continue Reading Study Found Ziritaxestat Ineffective in Improving IPF Lung Function
Nanoparticles Delivering mRNA Gene Editing Solutions to the Lungs Can Combat Genetic Diseases
source: shutterstock.com

Nanoparticles Delivering mRNA Gene Editing Solutions to the Lungs Can Combat Genetic Diseases

  Treatment advances are occurring daily in the field of rare disease. As researchers hone their strategies and tools, new technologies are emerging with the potential to significantly impact patients…

Continue Reading Nanoparticles Delivering mRNA Gene Editing Solutions to the Lungs Can Combat Genetic Diseases
Ifenprodil for IPF Earns Orphan Drug Designation
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

Ifenprodil for IPF Earns Orphan Drug Designation

In the United States, Orphan Drug designation is granted to drugs or biologics intended to treat, diagnose, or prevent rare diseases or conditions. These are defined as conditions affecting fewer…

Continue Reading Ifenprodil for IPF Earns Orphan Drug Designation
ICYMI: EI-1071 for IPF Earns Orphan Drug Status
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

ICYMI: EI-1071 for IPF Earns Orphan Drug Status

  According to an August 2022 news release from biotechnology company Elixiron Immunotherapeutics (“Elixiron”), EI-1071, a therapy for patients with idiopathic pulmonary fibrosis (IPF), recently earned Orphan Drug designation from…

Continue Reading ICYMI: EI-1071 for IPF Earns Orphan Drug Status
Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
https://pixabay.com/en/hand-world-ball-keep-child-earth-644145/

Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…

Continue Reading Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

European Study Demonstrates Need for Faster Diagnosis and Improved Counseling for Pulmonary Fibrosis Patients

A recent study has uncovered just how many people with pulmonary fibrosis (PF) do not receive an immediate diagnosis. This study conducted in Europe was published in Frontiers of Medicine.…

Continue Reading European Study Demonstrates Need for Faster Diagnosis and Improved Counseling for Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis: Antifibrotic Therapy Can Curb Exacerbations and Mortality
source: pixabay.com

Idiopathic Pulmonary Fibrosis: Antifibrotic Therapy Can Curb Exacerbations and Mortality

According to a story on medicaldialogues.in, a recent study has determined that antifibrotic treatment can reduce the rate of mortality and acute exacerbations in people living with idiopathic pulmonary fibrosis…

Continue Reading Idiopathic Pulmonary Fibrosis: Antifibrotic Therapy Can Curb Exacerbations and Mortality